KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, René Westhovens, Daniel W T Ching, Osvaldo Daniel Messina, Gerd R Burmester, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S Sundy, Tsutomu Takeuchi

Mod Rheumatol 32(2) 273-283

PMID34910203
PMCID-
DOI10.1093/mr/roab021
发表日期2021-12-15
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure. METHODS: Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week global Phase 3 study. Patients with RA and limited or no prior MTX exposure were randomised in a 2:1:1:2 ratio to filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, or MTX. Maximum MTX dose was 15 mg/week. Primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 24. RESULTS: Week 24 ACR20 rates in Japanese patients were 82.6%, 90.9%, 83.3%, and 80.0% for filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, and MTX, respectively. Greater ACR20 rates with filgotinib vs MTX occurred at Week 2. Greater proportions receiving filgotinib vs MTX achieved DAS28-CRP <2.6 at Weeks 12 and 24. Adverse event rates were comparable across treatments and between the Japanese and overall populations. CONCLUSIONS: While Week 24 ACR20 rates were similar, filgotinib provided faster responses and higher remission rates vs MTX. In Japanese patients with RA and limited or no prior MTX exposure, filgotinib was generally well tolerated.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。